Effect of omega-3-fatty acids versus placebo on clinical symptoms of patients with major depressive disorder

Effect of omega-3-fatty acids versus placebo on clinical symptoms of patients with major depressive disorder: a double blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201705249014N164

Enrollment

Registered

2017-06-08

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Severe depressive episode without psychotic symptoms

Interventions

Intervention 1: Intervention group: Routine treatment plus omega-3 capsule 100 mg daily for 12 weeks. Intervention 2: Control group: Routine treatment plus placebo capsule daily for 12 weeks.

Treatment - Drugs

Placebo

Intervention group: Routine treatment plus omega-3 capsule 100 mg daily for 12 weeks.

Control group: Routine treatment plus placebo capsule daily for 12 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age of 18 to 65 years; major depressive disorder Exclusion criteria: Pregnancy or breastfeeding; narcotic addiction; psychosis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depressive symptoms. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.;Sleep disorder. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.;Social competencies. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.;Physical activity. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.;Cognitive performance. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.	—

Measure

Time frame

Depressive symptoms. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.;Sleep disorder. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.;Social competencies. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.;Physical activity. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.;Cognitive performance. Timepoint: before intervention and 6 and 12 weeks after intervention. Method of measurement: using standard questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Sadeghi

Sina Hospital

sadeghiali196@gmail.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026